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Abstract: Lennox-Gaustaut syndrome is an electroclinical epilepsy syndrome characterized 
by the triad of electroencephalogram showing diffuse slow spike-and-wave discharges and 
paroxysmal fast activity, multiple intractable seizure types, and cognitive impairment. The intrac-
tability to seizure medications and cognitive impairment gives rise to eventual institutionalized 
patient care. Only a small subset of seizure medications has been shown to be helpful in seizure 
control. Most patients take up to 3 medications at high therapeutic dosing and are susceptible 
to medication-induced side effects. The lack of medication efﬁ  cacy in seizure control has led 
one meta-analysis to conclude that there is no single medication that is highly efﬁ  cacious in 
controlling seizures in this syndrome. On this background, a new and structurally novel seizure 
medication, ruﬁ  namide, has been found to be beneﬁ  cial in the treatment of seizures in this 
syndrome. In a multicenter, double-blinded, randomized, placebo-controlled study, ruﬁ  namide 
was found to reduce seizures by over 30%. More importantly, it reduced the frequency of the 
seizure type that induces most of the morbidity of this syndrome, the drop seizure, by over 
40%. There were few side effects, the medication was well tolerated, and in the open labeled 
extension study, tolerance was not found. In this review, we describe the main electroclinical 
features of Lennox-Gaustaut syndrome and summarize the few controlled studies that have 
contributed to its rational treatment. Currently, there is no single agent or combination of 
agents that effectively treat the multiple seizure types and co-morbidities in this syndrome. 
Our focus will be on the role of the new medication ruﬁ  namide in seizure reduction in patients 
with Lennox-Gaustaut syndrome.
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Introduction
The Lennox-Gaustaut syndrome is a catastrophic pediatric syndrome characterized 
by the electroclinical features of (1) electroencephalogram (EEG) showing abnormal 
background, diffuse slow spike-and-wave complexes (1.5–2.5 Hertz) and paroxysmal 
fast rhythms (10 Hertz), the latter may only occur in sleep; (2) multiple types of epilep-
tic seizures typically including tonic, typical absence, and drop attacks; and (3) slow 
mental development and/or behavioral disturbance.1–3 The long-term prognosis is poor 
because the majority of patients are medically refractory to antiseizure drugs (AEDs), 
have frequent episodes of status epilepticus, and severe cognitive impairment. Due to 
these factors, most patients eventually required institutional care.
Treatment is unsatisfactory. The ﬁ  nding of multiple seizure types, and exacerbation 
of certain seizures by the very medication used to stop other seizure types, often leads 
to over-dosing of medication, ineffective treatment, and pronounced expression of side 
effects. Many, if not all patients, are on polytherapy. Only a small subset of AEDs 
has found to be efﬁ  cacious in treatment of seizures associated with Lennox-Gaustaut 
syndrome. Even using these seizure medications, up to 96% of patients with Lennox-
Gaustaut syndrome have seizures that are refractory to treatment.4,5Therapeutics and Clinical Risk Management 2009:5 272
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Against this background of partially effective treatments, 
a recent double-blind, randomized, placebo-controlled study 
found that a new seizure medication, ruﬁ  namide, reduced 
overall seizure frequency and in particular, tonic-atonic 
seizures in Lennox-Gaustaut syndrome.6 Based on the data 
derived from this study, the United States Food and Drug 
Administration (FDA) approved ruﬁ  namide for adjunctive 
treatment in patients with Lennox-Gaustaut syndrome in late 
2008. Ruﬁ  namide has been approved in Europe since early 
2007 for add-on treatment in this syndrome.
In this review, we will discuss the natural history and 
management of the electroclinical syndrome of Lennox-
Gaustaut. In particular, our review will concentrate on the 
pharmacological properties and use of ruﬁ  namide in the 
context of the current knowledge of treatment for this medi-
cally intractable condition.
Lennox-Gaustaut syndrome
Lennox-Gaustaut syndrome is a catastrophic epileptic 
encephalopathy of childhood. Gibbs et al7 ﬁ  rst described 
the EEG pattern of slow spike and wave with Lennox, and 
his colleagues Lennox and Davis,8 together with Dravet9 
and Gaustaut et al10 further reﬁ  ned the clinical picture of the 
early onset of multiple seizure types and mental deﬁ  ciency. 
Although this syndrome has a long history in the epilepsy 
literature, there is no consensus of what minimal features are 
required for diagnosis when one of the triad of EEG or clinical 
ﬁ  ndings is missing. The deﬁ  nition is problematic as all features 
may not be present at a given period of the syndrome and the 
slow spike-and-wave pattern may be seen in other epileptic 
encephalopathies. Most, however, require two absolute criteria 
of (1) interictal, diffuse slow-spike-and-wave discharges on 
the EEG and (2) frequent and multiple seizure types, includ-
ing tonic, atypical absences, and drop attacks together with 
supporting ﬁ  ndings such as cognitive impairment, medically 
refractory seizures and paroxysmal fast activity in sleep.4,11
Electroclinical features
The age of onset is usually in early childhood between the 
ages of 1 and 8 years with peak at 3 to 5 years of age.12 
Onset can vary, as some patients do not express their ﬁ  rst 
seizure until the second decade.13 Those with Down’s syn-
drome usually do not manifest the full syndrome until about 
10 years of age.14 This syndrome accounts for approximately 
1% to 10% of all childhood epilepsies.4,15 However, the real 
ﬁ  gure is likely 4% as most patients with Lennox-Gaustaut 
syndrome are seen in tertiary epilepsy centers accounting for 
the higher estimates of incidence.16,17
The etiology of the Lennox-Gaustaut syndrome is diverse 
with both cryptogenic and symptomatic causes. Symptom-
atic cases are due to a variety of diffuse gray matter lesions 
such as hypoxic-ischemia, infection, malformation of corti-
cal development, chromosomal abnormalities, and head 
trauma.18 Cryptogenic etiology accounts for approximately 
25% to 33% of patients.4,18,19 Lennox-Gaustaut syndrome can 
follow other epileptic encephalopathy syndromes, in par-
ticular, West syndrome and Ohthara syndrome.20,21 In some 
studies, up to 25% of all patients have a history of West syn-
drome.18,15,20 The progression of EEG ﬁ  ndings and multiple 
seizure types from hypsarrhythmia, suppression-bursts, and 
epileptic spasms suggests age-related factors in the evolution 
of the electroclinical syndrome of Lennox-Gaustaut.
The characteristic interictal EEG pattern of slow spike-
and-wave complex (Figure 1) was initially described by Gibbs 
et al.7 The record is dominated by 1.5 to 2.5 Hertz spike/
sharp-and-wave complex, which are diffuse and maximum 
bifrontally but sometimes can be conﬁ  ned to the anterior or 
posterior head regions. Although the slow spike-and-wave 
pattern is fairly symmetrical, a shifting asymmetry in different 
bursts is common.18 The duration of the complexes can vary, 
but they often appear in prolonged sequences as long as half 
of the routine EEG record without clinical change. For this 
reason, the slow spike-and-wave activity is usually considered 
an interictal pattern. The slow spike-and-wave complexes are 
sometimes not present on the EEG at the onset of seizures, 
but can appear over 1 year later.22 Non-rapid eye movement 
sleep augments slow spike-and-wave complex expression in 
about 95% of patients with longer duration of discharges.18
Paroxysmal fast activity (Figure 2) is the second char-
acteristic EEG pattern of Lennox-Gaustaut syndrome and 
occurs predominantly or sometimes exclusively during 
nonrapid eye movement sleep.15 Discharge frequency is 
usually between 10 and 25 Hertz, preceded or followed 
by generalized sharp and slow wave complexes, and has a 
duration of 1 to 9 seconds. The spike paroxysms show little 
change in frequency throughout the burst. The discharges 
are widespread in distribution and bilaterally synchronous 
over both hemispheres. Shifting asymmetries are common. 
When seen during the waking state, paroxysmal fast activity 
is usually ictal and associated with tonic seizures. However, 
in its most common ﬁ  nding during nonrapid eye movement 
sleep, the EEG pattern is usually not associated with obvious 
clinical signs. When not associated with clinical signs, this 
pattern may sometimes be subclinical seizures.
The background frequency is slow for age in 65% to 
90% of patients.22 The degree of slowing correlates with the Therapeutics and Clinical Risk Management 2009:5 273
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Figure 1 This is an EEG of a 5-year-old girl with Lennox-Gaustaut syndrome showing generalized spike-and-wave discharges. The frequency of spike-and-wave activity 
is 2.5 Hertz.
300 uV
Figure 2 This is an EEG of a 8-year-old boy with Lennox-Gaustaut syndrome demonstrating paroxysmal fast activity during sleep. There were no observable clinical changes 
noted during the discharge.Therapeutics and Clinical Risk Management 2009:5 274
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severity of intellectual impairment and is a poor prognosis 
for normal development.18
One of the hallmarks of Lennox-Gaustaut syndrome is the 
presence of multiple seizure types, with as many as 95% of 
patients having multiple seizures.12 The most characteristic 
seizures are tonic and are reported in over 75% of all patients 
with Lennox-Gaustaut syndrome under the proper recording 
conditions.12 Tonic seizures have a range of semiology, from 
global involvement of the whole body to a slight upward 
movement of the eyes associated with a brief change in the 
respiratory and heart rate. Atypical absence seizures are also 
common in Lennox-Gaustaut syndrome with over 75% of 
patients expressing this seizure type.15 The typical semiology 
is the progressive impairment of consciousness that is usually 
incomplete and recovers gradually at the end of the event. 
This may be difﬁ  cult to recognize in a cognitively impaired 
child. The third most common seizure semiology are drop 
attacks which occur in about 33% to 66% of all patients.15 
These seizures are characterized by a sudden forward or back-
ward falls which take place in a fraction of a second. Drop 
attacks caused by exclusive loss of muscle tone are rare.23 
Most drop attack seizures are brief motor events associated 
with a fall and represent either myoclonic-atonic, myoclonic, 
or tonic seizures.23,24 The majority of the epileptic falls in 
patients are the result of tonic falls.23,24 These seizures are 
the most difﬁ  cult to treat and most dramatic to witness due 
to bodily injuries involving the face and head. Other type of 
seizures such as generalized tonic-clonic, myoclonic jerks, 
and focal seizures occur in Lennox-Gaustaut syndrome but 
are not an integral part of the syndrome.
More than 60% of patients with Lennox-Gaustaut syn-
drome will have a bout of status epilepticus.15 The two most 
common types of status epilepticus are tonic and atypical 
absence. Tonic status is often induced by intravenous (iv) 
administration of benzodiazepine. The usual scenario is a 
patient who is experiencing atypical absence status epileptics 
and is given iv benzodiazepine to stop the atypical status.25,26 
Atypical absence status epilepticus is often unrecognized 
due to an already cognitively impaired child who looks 
just a little more lethargic, irritable, or tired. The event is 
usually characterized by a mild clouding of consciousness 
that ﬂ  uctuates and may last for hours to more than a week. 
The EEG during a status event is often difﬁ  cult to discern 
from the interictal EEG. The slow spike-and-wave complex 
discharges may become more persistent or an evolution into 
an atypical hypsarrhythmia pattern may occur.27
The majority of patients with Lennox-Gaustaut syn-
drome continue to have medically refractory epilepsy, 
neurocognitive problems and frequent episodes of status 
epilepticus. Unfortunately, approximately 50% of patients 
continue to have the full syndrome into adulthood. Most of 
the remaining patients have varying severity of epilepsy and 
cognitive problems with institutional care the norm. Only 
approximately 10% will fully remit their seizures, but many 
of these patients remain with cognitive problems.
Treatment
The intractability of seizures to medications and multiple 
seizure types lead to the use of polytherapy, often at 
high doses. Using high doses of medications increase the 
likelihood of drug side effects. In this syndrome, certain 
medications used to treat one type of seizure may exac-
erbate expression of other seizure types. Both carbam-
azepine and phenytoin used to treat tonic and generalized 
tonic clonic seizure may exacerbate atypical absence and 
myoclonic seizures. Intravenous benzodiazepines may 
induce tonic status epilepticus.25,26 Although extensively used 
in treatment, benzodiazepines may produce undesirable side 
effects of drooling, incoordination and drowsiness. Together, 
polytherapy, restricted range of efﬁ  cacious medications and 
side effects of drugs on the tapestry refractory seizures, make 
treatment unsatisfactory.
Although not tested in formalized clinical trials, valproic 
acid is often used as ﬁ  rst line therapy. Three double-blind, 
randomized, placebo-controlled trials have shown that several 
of the newer AEDs, lamotrigine, felbamate, and topiramate, 
are efﬁ  cacious as adjunctive therapy (Tables 1 and 2).28–30 
Felbamate treated patients had a mean reduction in total 
seizure frequency of 19%, compared with 4% increase 
with placebo and complete cessation of atonic seizures in 
17.9%, compared to 0% in the untreated group.29 Patients 
treated with lamotrigine reported a median reduction in total 
seizures of 32% compared with 9% increase with placebo 
and when subdivided into speciﬁ  c seizure types, there was 
a median reduction in drop attacks of 34% compared to 9% 
in the placebo group.28 Patients in the topiramate study had a 
median reduction of 20.6% reduction in total seizures, com-
pared to 8.8% reduction in the placebo group and a 14.8% 
decrease in drop seizures, compared to a 5.1% increase in 
the placebo arm.30 These studies were short in duration, 
with maintenance phase of the study lasting 8 to 16 weeks. 
In reviewing these studies in a meta-analysis, a Cochrane 
review concluded that no single AED could be considered 
highly efﬁ  cacious although lamotrigine, topiramate, and 
felbamate may be helpful as add-on treatment for patients 
with Lennox-Gaustaut syndrome.31Therapeutics and Clinical Risk Management 2009:5 275
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There have been other studies using non-medical 
modalities to investigate seizure control. In a large multi-
center study of 50 patients with Lennox-Gaustaut syndrome 
implanted with the vagus nerve stimulator, 43% of patients 
had a 50% or more reduction in seizure frequency and sub-
sequently a 56% reduction, after 1 and 3 months of use.32 
Patients undergoing corpus callostomy had a 90% reduc-
tion in drop attacks in 44/52 patients followed for a mean 
of 40 months.33 Unfortunately, there are little comparative 
data with AEDs.
Against this background of seizure intractability and lack 
of efﬁ  cacy in seizure control, a new medication has been 
recently approved for use in patients with Lennox-Gaustaut. 
Based on data from a recent published study by Glauser et al,6 
the FDA has approved the medication, ruﬁ  namide, for use 
in this syndrome.
Ruﬁ  namide
Ruﬁ  namide is an orally active, structurally novel compound 
(1-[(2,6-difluorophenyl)methyl]-1 hydro-1,2,3-triazol-4 
carboxamide) that is structurally distinct from other AEDs 
(Figure 3).34 In experimental models, ruﬁ  namide suppresses 
neuronal hyper-excitability by prolonging the inactiva-
tion phase of voltage-gated sodium channels.35 In several 
animal models, ruﬁ  namide has been shown to have broad 
spectrum of anticonvulsant activity. Ruﬁ  namide suppresses 
maximal electroshock (MES)-induced seizures in both rats 
and mice models, and chemically-induced seizures in mice. 
Rufinamide was also effective in the pentylenetetrazol 
(PTZ) test in mice.36 For a complete summary of the studies 
investigating the pharmacology of ruﬁ  namide, the reader 
is referred to an excellent recent review by Perucca et al.37 
Another review of ruﬁ  namide, which is more clinically based, 
can be found in an article by Arroyo.38
Pharmacokinetics
Ruﬁ  namide is a lipophilic compound with a log p-value 
of 0.88 and water solubility of 40 mg/L.39 In a study of 
3 healthy volunteers, ruﬁ  namide was extensively absorbed, 
with 85% of the drug absorbed. The mean maximum 
plasma concentration (Cmax) of ruﬁ  namide was reached within 
6.6 hours following a single dose of 400 mg.40,41 Absorption 
is thought to be dissolution rate-limited rather than perme-
ability rate-limited and absorption is likely to take place 
throughout most of the small bowel and possibly even part 
of the large bowel.37 The inﬂ  uence of food was evaluated 
in three studies in healthy subjects who were given single 
doses of ruﬁ  namide. Taking ruﬁ  namide at least 1 hour from 
meal times was not found to signiﬁ  cantly affect drug plasma 
ruﬁ  namide concentrations. However, when ruﬁ  namide phar-
macokinetics are compared after a high-fat meal and after a 
14-hour fast, differences in bioavailability become clearly 
evident, and may have clinical relevance. After the high fat 
meal, Cmax increased 56% and the area under the plasma 
concentration curve (AUC) increased by 36%.37 Therefore, 
administering ruﬁ  namide during intervals of prolonged 
fasting may lead to appreciably lower plasma ruﬁ  namide 
levels, and therefore may alter seizure protection.
Ruﬁ  namide is extensively metabolized to a carboxylic 
acid derivative (CGP 47292) and to the glucuronide conjugates 
Table 1 Methodological features of randomized, double-blind controlled trials of adjunctive drug treatment for Lennox-Gaustaut syndromea
Felbamate Lamotrigine Topiramate Ruﬁ  namide
Number of patients 73 169 98 138
Age range (years) 4–36 3–25 2–29 4–36
EEG criteria SSW SSW SSW SSW
Number of seizures
per month
90 15 60 90
Seizure frequency 
determination
Diaryb Diary Diary Diary
AEDs 1–2 1–3 1–2 1–3
Time course (weeks)
 Baseline 4 4 4 4
 Titration 2 6 3 2
 Maintenance 8 10 8 10
aOnly studies that showed a signiﬁ  cant reduction in seizures are presented. Data from derived from Glauser et al6 and Hancock and Cross.31
bThis study also used video EEG.
Abbreviations: AEDs, antiseizure drugs; EEG, electroencephalogram; SSW, diffuse slow spike-and-wave complexes.Therapeutics and Clinical Risk Management 2009:5 276
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of the compound CGP 47292 with minimal amounts excreted 
unchanged in the urine and feces. Less than 7% of the dose 
is excreted in the urine as the acyl-glucuronide metabolite 
and none of this metabolite was found in the feces.40 Human 
liver microsome studies indicate that ruﬁ  namide is not 
metabolized via the cytochrome P450 system. The principal 
route is hydrolysis of the carboxamide by carboxylesterases 
into a pharmacologically inactive compound CGP 47292. 
The carboxylesterases are susceptible to induction by cyto-
chrome P450 inducers.42
In a multiple-dose study in patients with epilepsy, 
400 mg given twice a day, the elimination half-life (T1/2) was 
6.9 hours on day 1 and 7 was unchanged on day 35.37
There was no difference in ruﬁ  namide pharmacokinet-
ics between older (66–77 years) and younger (18–40 years) 
healthy volunteers, in either single- or multiple-dosing 
conditions.43 In a study of 16 children with epilepsy between 
2 and 17 years of age treated with 10 or 30 mg/kg daily for 
2 weeks, the pharmacokinetics were similar to that reported 
in adult patients.44 Taken together, the data suggest that 
ruﬁ  namide requires no age-related dose adjustments for 
children and elderly populations.
Due to the lack of renal excretion of unchanged drug, 
renal impairment has no signiﬁ  cant inﬂ  uence on ruﬁ  namide 
pharmacokinetics. In this same study, steady state dosing was 
evaluated in patients undergoing hemodialysis and it was 
concluded that no speciﬁ  c dose adjustment is likely neces-
sary for patients undergoing hemodialysis.37 No studies have 
examined ruﬁ  namide and patients with hepatic disease.
The extent of plasma protein binding in vitro is low, 
ranging from 26% to 34% at total concentrations of 0.25 to 
19.6 μg/mL.37 Most of the binding is to serum albumin, 
suggesting low potential for drug–drug interactions.
Drug–drug interactions
There have been no speciﬁ  c pharmacokinetic studies on 
ruﬁ  namide interactions with other AEDs. The effects of 
other AEDs on plasma ruﬁ  namide concentrations were 
investigated in pooled population pharmacokinetic analysis 
of data collected in efﬁ  cacy and safety trials.37, 45 Ruﬁ  namide 
did not alter the CL/F of topiramate or valproic acid. At typi-
cal steady state levels of 15 μg/mL associated with a dose 
Table 2 Overview of key seizure outcomes of randomized, 
double-blind, controlled trials of adjunctive drug treatment for 
Lennox-Gaustaut syndromea
Study Outcomes vs Placebo
Felbamate Complete cessation of seizures
  10.8% vs 2.7% (p = 0.2, RR = 3.9, CI = 0.5–33.2)
Complete cessation of atonic seizures
  17.9% vs 0% (p = 0.1, RR = 5.7, CI = 0.5–49.8)
Complete cessation of tonic-clonic seizures
  43.7% vs 7.7% (p = 0.08, RR = 5.7, CI = 0.8–40.5)
Mean change in total seizure frequency
  19% vs 4% (p = 0.002)
Lamotrigine Mean reduction in drop attacks
  34% vs 9%
Responder rateb for drop attacks
Responder rateb for tonic-clonic seizures
  43.3% vs 20.3% (RR = 2.1, CI = 2.0–3.8)
Responder rateb for total seizures
  33.3% vs 15.7% (RR = 2.1, CI = 2.0–3.8)
Mean change in total seizure frequency
  32% vs 9% (increase)
Topiramate Mean change in drop attacks
  14.8% vs 5.1% (increase) (p = 0.04)
Complete cessation of drop attacks
  2.2% vs 0% (RR = 3.3, CI = 0.1–7.8)
Responder rateb for drop attacks
   45.6% vs 20.0% (RR = 2.9, CI = 0.8–10.2 for 75% 
reduction, RR = 2.0, CI = 0.9–4.6 for 50%–74% 
reduction)
Mean reduction in total seizures
  20.6% vs 8.8% (p = 0.037)
Ruﬁ  namide Median reduction of tonic-atonic seizures
  42.5% vs 1.4% (p  0.0001)
Responder rateb for tonic-atonic seizures
  42.5% vs 16.7% (p = 0.0020)
Median reduction in total seizures
  32.7% vs 11.7% (p = 0.0015)
Patients with improvement in seizure frequency
 53.4%  vs  30.6%  (p  = 0.0041)
aOnly studies that showed a signiﬁ  cant reduction in seizures are reported. Data from 
Cochrane review31 and Glauser et al.6
bResponder rate deﬁ  ned as % patients achieving at least 50% reduction from baseline 
in seizure frequency.
Abbreviations: CI, conﬁ  dence interval; RR, relative risk.
F
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Figure 3 The molecular structure of ruﬁ  namide (1-[(2,6-diﬂ  uorophenyl) methyl]-1 
hydro-1,2,3-triazole-4 carboxamide). Ruﬁ  namide is a triazole derivative.Therapeutics and Clinical Risk Management 2009:5 277
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of 40 to 50 mg/kg/day, ruﬁ  namide increased the CL/F of 
carbamazepine by 15% in children, 9% in adolescents, and 
8% in adults. This predicts a reduction in carbamazepine 
steady state levels of 13%, 8%, and 7%, respectively. At the 
same ruﬁ  namide dose there was an increase in the CL/F of 
lamotrigine by 16%, 11%, and 8% in children, adolescents, 
and adults, respectively. This would suggest a mild reduction 
in lamotrigine concentrations with co-administration of ruﬁ  n-
amide. Ruﬁ  namide decreased the CL/F of both phenobarbital 
and phenytoin by 12%, 9%, and 7% for phenobarbital and 
17%, 9% and 6% for phenytoin in children, adolescents, and 
adults, respectively. The prediction would be an proportional 
increase in phenobarbital concentration, but due to non-linear 
elimination kinetics of phenytoin, estimations of phenytoin 
concentrations cannot be made with precision.
The administration of valproic acid was found to 
increase ruﬁ  namide concentrations. In a pooled analysis 
of 400 children, ruﬁ  namide concentration was increased 
by 60% to 70% at an average steady state concentration of 
valproic acid of 100 μg/mL. At the same average steady 
state concentration of valproic acid, adolescents and adults 
has smaller increases of ruﬁ  namide concentrations, 26% 
and 16%, respectively. In the latter two analyses, the steady 
state concentrations of valproic acid were 88 and 71 μg/mL, 
respectively. Although the exact differences in valproic acid 
concentrations that would result in altering adolescent and 
adult concentrations of ruﬁ  namide cannot be fully ruled 
out, it is likely that there is an age related affect of valproic 
acid on ruﬁ  namide. There were no signiﬁ  cant differences 
between males and females. Analysis indicated that plasma 
concentration of ruﬁ  namide is not signiﬁ  cantly affected by 
lamotrigine, topiramate, or benzodiazepines.
In contrast to valproic acid, co-administration of carba-
mazepine, vigabatrin, phenytoin, phenobarbital, or prima-
done was found to decrease plasma ruﬁ  namide steady state 
concentrations.37Again, the effect was more pronounced in 
children. Carbamazepine reduced plasma concentrations 
of ruﬁ  namide by approximately 24%, 19%, and 21% and 
vigabatrin decreased concentrations by 28%, 18%, and 
14% in children, adolescents, and adults, respectively. The 
effects of the remaining enzyme-inducing AEDs, phenytoin, 
phenobarbital and primadone, were pooled. Ruﬁ  namide 
concentrations were reduced by 44%, 30%, and 25% in 
children, adolescents and adults, respectively. The clinical 
relevance of these changes is unknown, but the indication 
is that interacting AEDs should be monitored after addition 
or withdrawal as well as ruﬁ  namide concentrations if the 
clinical situation indicates it.
Safety
The relationship between plasma ruﬁ  namide concentrations 
and adverse effects has been assessed in 1398 patients com-
prising all patients in pooled controlled studies and clinical 
studies.37,45 The most common side effects were dizziness 
(13%), fatigue (12%), nausea (9%), vomiting (7%), diplopia 
(6%), and somnolence (4%). The factors that increased the 
probability of adverse events were plasma concentrations 
of AEDs (including ruﬁ  namide), age, gender, and weight. 
There was an association with mildly increased side effects in 
adults compared to children, increased body weight, female 
sex, and plasma ruﬁ  namide plasma concentration.
Ruﬁ  namide side effect proﬁ  le is relatively narrow and 
to date, non-life threatening when compared to lamotrigine, 
topiramate and felbamate. The use of felbamate has been 
restricted following reports of idiosyncratic reactions of 
aplastic anemia and hepatic failure.47 Lamotrigine has been 
found to cause potential life-threatening dermatologic reac-
tion, especially in the context of concomitant dosing of 
multiple AEDs.48 Topiramate can produce oligohydrosis, 
hyperthermia, metabolic acidosis and glaucoma.49,50
In healthy volunteers treated with ruﬁ  namide for 18 days, 
the QT interval was shown to decrease in a dose-dependent 
manner.51 This would seem of little clinical signiﬁ  cance. 
However, recently 22 patients have been described to 
have short QT syndrome.52 This syndrome presents with 
episodes of syncope, ventricular arrhythmia, and possible 
sudden death. Ruﬁ  namide would certainly be contraindi-
cated in patients with this syndrome as well as other drugs 
that decrease the QT interval. The extent of this disorder is 
unknown but caution should be used in patients with history 
of abnormal electrocardiogram demonstrating short QT 
interval or family history of unexplained cardiac arrhythmia 
or sudden death.
Ruﬁ  namide and Lennox-Gaustaut 
syndrome
Lennox-Gaustaut syndrome is a catastrophic pediatric 
epilepsy syndrome, where over 90% of patients remain with 
medically refractory seizures and have severe cognitive 
defects and most often are institutionalized. Although some 
medical treatments are helpful, none have signiﬁ  cantly 
inﬂ  uenced the treatment of this syndrome.31
As we have previously described, ruﬁ  namide is a struc-
turally novel compound that most likely limits the excessive 
ﬁ  ring of sodium-dependent potentials. The pivotal study was 
a multicenter double blinded, randomized, placebo-controlled 
study (Tables 1 and 2).6 The requirements for entry were Therapeutics and Clinical Risk Management 2009:5 278
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multiple seizure types which had to include atypical absence 
seizures and drop attacks (deﬁ  ned as tonic-atonic or astatic 
seizures), a minimum of 90 seizures the month before study 
entrance (the 28-day baseline period) and an EEG pattern of 
slow spike-and-wave complexes (2.5 Hertz), and a ﬁ  xed 
regimen of 1 to 3 concomitant AEDs. MRI or CT studies had 
to demonstrate that patients did not have structural criteria 
of a progressive lesion. The 28-day baseline period was 
followed by an 84-day, double-blind, placebo-controlled, 
parallel group treatment period. Ruﬁ  namide was dosed to 
a target dose of 45 mg/kg/day and this dose was reached 
within 7 days. Patient characteristics between the two treat-
ment groups were similar, age range from 4 to 30 years with 
median age of 12 years and median weight of 34.7 kg.
The ﬁ  ndings were dramatic. There was an overall reduc-
tion in seizures by 32.7% per 28 days, compared to 11.7% in 
the placebo group (p = 0.0015). Moreover, there was a 42.5% 
decrease in drop seizures frequency, compared to the placebo 
increase of 1.4% (p  0.0001). Due to seizure intractability 
to AEDs and high morbidity, the decrease in drop seizures 
is viewed as the primary outcome variable for treatment of 
Lennox-Gaustaut syndrome.51 When the results are adjusted 
to treatment size, ruﬁ  namide decreased drop attacks by 41.1%, 
compared to lamotrigine reduction of 19.9% and topiramate 
of 14.8%. The authors indicate that caution should be used, 
as data from cross-trial analysis with different methodologies 
were used to report efﬁ  cacy outcomes.6
Ruﬁ  namide reduced the frequency of atypical absence 
seizures per 28 days (p  0.03) and tonic seizures (p  0.02). 
No patients were seizure free during the study. Three patients 
developed status epilepticus, but status events are common in 
this syndrome, and therefore it was not clear if this was due 
to ruﬁ  namide dosing or the natural history of the syndrome. 
Although only presented in abstract form, 123 patients contin-
ued to receive medication in the open-labeled extension phase 
at a median dose of 1800 mg/day (range 103–4265 mg/day) 
for a median duration of 432 days (range 10–1149 days). 
The median total seizure frequency reduction observed at 
12 weeks was maintained.52 Furthermore, 21.3% of patients 
had a 75% reduction in total seizures during the extension 
study. These data imply that tolerance may not occur with 
ruﬁ  namide use, at least over a 400-day period.
In the short double-blind study, there were few side 
effects, only somnolence (24.3%) and vomiting (21.6%) 
being the most cited adverse events. Treatment was also 
associated with lower incident of cognitive/psychiatric 
untoward effects (17.6% and 23.4%, respectively). In the 
open-labeled study, the most common adverse events were 
vomiting (30.6%), pyrexia (25.8%), upper respiratory 
infection (21.8%) and somnolence (21%). The extended 
study indicates that central nervous system side effects are 
unchanged in long term exposure of ruﬁ  namide.
Conclusion
The treatment of the catastrophic pediatric epilepsy 
syndrome, Lennox-Gasutaut syndrome remains unsatis-
factory. Most patients remain having intolerable medi-
cally refractory seizures, cognitive delays and become 
institutionalized. This past year the FDA approved a new 
medication for adjunction treatment of this syndrome. Ruﬁ  n-
amide is a new and structurally novel seizure medication 
that has proven to decrease the total frequency of seizures, 
in particular, the most devastating of the seizure types, drop 
seizures. It has few side effects and is well tolerated. It has the 
advantage of full therapeutic dosing within 1 week, whereas 
other approved medications, lamotrigine and topamax, can 
take up to 2 months to reach therapeutic values. There does 
not seem to be a change in efﬁ  cacy during long-term use. 
It has few interactions with other seizure medications that 
are likely needed to help control the multiple seizure types 
found in this syndrome.
It is not clear if and how ruﬁ  namide will synergize with 
the nonmedical treatments of patients with Lennox-Gaustaut 
syndrome of corpus callosotomy and vagus nerve stimula-
tion. In addition, the medical context of ruﬁ  namide with 
other medications that are being developed and/or other 
medications that have been shown to reduce seizures in small 
open-labeled studies should foster a better recipe for medical 
and surgical management of this syndrome in the future.
Taken together, the data suggest that ruﬁ  namide is a 
viable adjunctive treatment for patients with the Lennox-
Gaustaut syndrome.
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